“肺炎1号”治疗2019冠状病毒病的临床疗效研究  

Clinical efficacy study on Corona Virus Disease 2019 treated with‘Pneumonia No.1 Formula’

作　　者：巴元明[1,2,3] 李伟男 王林群[6] 左新河 石全 沈银峰[4] 张雪荣[4] 陆定波 吴霞[1,2,3] 冯毅[1,2,3] 王小琴[1,2,3] 胡刚明 张馨[4] 姜楠 BA Yuan-ming;LI Wei-nan;WANG Lin-qun;ZUO Xin-he;SHI Quan;SHEN Yin-feng;ZHANG Xue-rong;LU Ding-bo;WU Xia;FENG Yi;WANG Xiao-qin;HU Gang-ming;ZHANG Xin;JIANG Nan(Hubei Provincial Hospital of TCM,Wuhan 430061,China;Affiliated Hospital of Hubei University of Chinese Medicine,Wuhan 430061,China;Hubei Academy of Traditional Chinese Medicine,Wuhan 430061,China;Hubei University of Chinese Medicine,Wuhan 430061,China;Hanchuan People’s Hospital,Xiaogan 432300,China)

机构地区：[1]湖北省中医院,武汉430061 [2]湖北中医药大学附属医院,武汉430061 [3]湖北省中医药研究院,武汉430061 [4]湖北中医药大学,武汉430061 [5]汉川市人民医院,孝感432300 [6]湖北中医药大学第一临床学院,武汉430061

出　　处：《中华中医药杂志》2020年第4期2178-2181,共4页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：湖北省科技厅新型肺炎应急科技攻关项目(No.2020FCA007);巴元明全国名老中医药专家传承工作室,第六批全国老中医药专家学术经验继承工作指导老师项目(No.国中医药人教发〔2017〕29号);湖北省中医院“昙华林名医”培养项目。

摘　　要：目的:观察“肺炎1号”治疗2019冠状病毒病(COVID-19)的临床疗效,为进一步指导临床救治提供依据。方法:选择2020年2月17日至29日湖北省中医院收治的新型冠状病毒肺炎患者69例,采用“肺炎1号”联合西医常规治疗,观察“肺炎1号”对COVID-19患者的临床症状、舌象、实验室检查结果及肺部CT改善情况。结果:共纳入69例患者,其中轻型1例,普通型66例,重型2例。新型冠状病毒核酸检测阳性48例(69.57%)、疑似2例(2.90%)、阴性19例(27.54%)。肺部CT肺纹理增多、增粗4例(5.80%),可见斑片影、磨玻璃样改变65例(94.20%)。治疗后,超敏C反应蛋白较治疗前显著降低(P<0.05)。患者发热、咳嗽、乏力等相关症状较治疗前显著好转(P<0.01)。退热时间最短1d,最长10d,平均(3.91±1.93)d。40例患者舌质红或绛逐渐转淡红,好转率为83.33%;34例患者白腻苔、厚腻苔、黄腻苔明显变薄,好转率为75.56%。新型冠状病毒核酸检测转阴时间最短2d,最长14d,平均(7.29±3.41)d。肺部CT病灶面积减小,变薄变淡,60例(86.96%)较前好转。纳入的69例患者,由普通型转重型2例(3.03%),无死亡病例,全部治愈出院。“肺炎1号”无明显不良反应。结论:“肺炎1号”结合西医常规治疗对COVID-19有较好的治疗作用,能快速稳定病情,阻断轻型、普通型向重型、危重型转化,改善患者症状且使用安全。Objective:To observe the clinical efficacy of Corona Virus Disease 2019(COVID-19)treated with Pneumonia No.1 Formula,and to provide evidence for further clinical treatment.Methods:A total of 69 COVID-19 patients from February 17th to 29th 2020 in Hubei Provincial Hospital of TCM were collected,who were treated with Pneumonia No.1 Formula and conventional western treatment,and the clinical symptoms,tongue manifestation,experimental results and pulmonary CT were observed.Results:A total of 69 patients were included,including 1 case of light type,66 cases of common type and 2 cases of sever type.There were 48 cases(69.57%)positive for NPV nucleic acid,2 cases(2.90%)suspected,and 19 cases(27.54%)negative.Pulmonary CT showed increased and enlarged pulmonary veins in 4 cases(5.80%),patchy lesions and ground glass changes in 65 cases(94.20%).After treatment,C reactive protein(CRP)was significantly decreased(P<0.05).The main symptoms of fever,cough,fatigue and other related symptoms were significantly improved(P<0.01).The shortest time for abatement of fever was 1d and longest was 10d,with the mean time of(3.91±1.93)d.In 40 patients,the tongue gradually turned light with red or dark red,the improvement rate was 83.33%,and in 34 patients,the tongue coating turned white,thick and yellow greasy to thin,the improvement rate was 75.56%.The shortest time for NPV nucleic acid to turn negative was 2d and the longest was 14d,with an average of(7.29±3.41)d.CT of the lung mainly showed that the area of the focus decreased,became thinner and lighter,60 cases(86.96%)were better than before.Of the 69 patients included,2 cases(3.03%)were transferred from the common type to the severe type.All patients were cured and discharged after treatment without death.There was no adverse reaction.Conclusion:‘Pneumonia No.1 Formula’has a good therapeutic effect on COVID-19,which can rapidly stabilize the disease,cut off light and common type to severe and critical illness,improve symptoms and safety,and is worthy of further promotion in clin

关 键 词：2019冠状病毒病 肺炎1号 中医药 前瞻性研究 瘟疫 疗效 

分 类 号：R259[医药卫生—中西医结合]